Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280332 | 0.97 | — | — | |
| SCHEMBL301587 | 0.97 | — | — | |
| SCHEMBL10871578 | 0.97 | — | — | |
| SCHEMBL19331 | 0.92 | — | — | |
| SCHEMBL310609 | 0.78 | ALDH1A1 (0.32) | ALDH1A1MAPK1 | |
| SCHEMBL5086 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2138806 | 0.73 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL2307899 | 0.70 | — | — | |
| SCHEMBL37824 | 0.70 | — | — | |
| SCHEMBL23290830 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | PRAMANA PHARMACEUTICALS INC. (CA) | 2024-07-16 | — | — | US | disclosed |
| US-12029728-B2 | Small molecules with anti-protozoan activity | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029731-B2 | Acyl benzo[d]thiazol-2-amine and their methods of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4380566-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| CN-118119389-A | Prodrugs and derivatives of des-phosphate nupharicin and uses thereof | 人类生物科学股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118076354-A | Methods of treating migraine with MNK inhibitors | 4E治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118076583-A | Methods and compositions for treating cancer | 安可诺瓦治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024107730-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ONCONOVA THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2008051318-A2 | SHAPE MEMORY POLYMERS | UNIVERSITY OF ROCHESTER (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007149873-A2 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149874-A1 | IMIDAZOLIDINONE KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007146981-A2 | 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES AS INHIBITORS OF PROTEIN KINASE C-ALPHA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146977-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | DJUNG JANE F | 2007-12-20 | — | — | US | disclosed |
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20060178350-A1 | 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes | UNIVERSITEIT GENT (BE) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293494-A1 | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines | PRKCA, PRKCG, PRKCH | ALDH1A1 4216/4885MAPK1 549/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | ALDH1A1 5/4885MAPK1 1764/4885 |
| US-12029731-B2 | Acyl benzo[d]thiazol-2-amine and their methods of use | BRCA1, ABAT, HDAC1 | ALDH1A1 306/4885MAPK1 3561/4885 |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | ALDH1A1 2088/4885MAPK1 610/4885 |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNA5, KCNH1, KCNK5 | ALDH1A1 888/4885MAPK1 974/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | ALDH1A1 5/4885MAPK1 1764/4885 |
| US-20060178350-A1 | 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes | NR3C2, PKD2, REN | ALDH1A1 59/4885MAPK1 4631/4885 |
| US-12037328-B2 | Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 | GPR119, GPR3, GPR39 | ALDH1A1 1111/4885MAPK1 1833/4885 |
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | ALDH1A1 3759/4885MAPK1 780/4885 |
| US-12029728-B2 | Small molecules with anti-protozoan activity | GBA3, CTSA, ITPA | ALDH1A1 3187/4885MAPK1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.